- Home
- GAME vs ATHA Comparison
GAME vs ATHA Comparison
Compare GAME & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GAME
- ATHA
- Stock Information
- Founded
- GAME 2011
- ATHA 2011
- Country
- GAME United States
- ATHA United States
- Employees
- GAME N/A
- ATHA N/A
- Industry
- GAME
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- GAME
- ATHA Health Care
- Exchange
- GAME Nasdaq
- ATHA Nasdaq
- Market Cap
- GAME 25.8M
- ATHA 21.0M
- IPO Year
- GAME 2009
- ATHA 2020
- Fundamental
- Price
- GAME $0.62
- ATHA $0.24
- Analyst Decision
- GAME Strong Buy
- ATHA Buy
- Analyst Count
- GAME 3
- ATHA 4
- Target Price
- GAME $3.67
- ATHA $11.25
- AVG Volume (30 Days)
- GAME 197.5K
- ATHA 218.6K
- Earning Date
- GAME 05-19-2025
- ATHA 05-14-2025
- Dividend Yield
- GAME N/A
- ATHA N/A
- EPS Growth
- GAME N/A
- ATHA N/A
- EPS
- GAME N/A
- ATHA N/A
- Revenue
- GAME $99,072,646.00
- ATHA N/A
- Revenue This Year
- GAME $102.01
- ATHA N/A
- Revenue Next Year
- GAME $17.88
- ATHA N/A
- P/E Ratio
- GAME N/A
- ATHA N/A
- Revenue Growth
- GAME 210.51
- ATHA N/A
- 52 Week Low
- GAME $0.50
- ATHA $0.22
- 52 Week High
- GAME $2.25
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- GAME 44.31
- ATHA 26.46
- Support Level
- GAME $0.56
- ATHA $0.22
- Resistance Level
- GAME $0.69
- ATHA $0.26
- Average True Range (ATR)
- GAME 0.08
- ATHA 0.03
- MACD
- GAME 0.00
- ATHA -0.00
- Stochastic Oscillator
- GAME 39.35
- ATHA 14.85
About GAME GameSquare Holdings Inc.
GameSquare Holdings Inc is engaged to revolutionize the way brands and game publishers connect with hard-to-reach Gen Z, Gen Alpha, and Millennial audiences. Its next generation media, entertainment, and technology help creators and maximize its brand partners return on investment. Its purpose-built platform, provide marketing and creative services, offer data and analytics solutions, and amplify awareness through FaZe Clan.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.